Joan Herman Sells 21,004 Shares of Paysign (NASDAQ:PAYS) Stock

Paysign, Inc. (NASDAQ:PAYS) EVP Joan Herman sold 21,004 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $12.38, for a total value of $260,029.52. Following the completion of the transaction, the executive vice president directly owned 648,321 shares of the company’s stock, valued at approximately $8,026,213.98. This represents a 3.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Paysign Trading Down 0.6%

Shares of PAYS opened at $12.34 on Friday. The stock has a 50 day moving average of $11.53 and a 200 day moving average of $8.04. The company has a market capitalization of $696.72 million, a price-to-earnings ratio of 47.46 and a beta of 0.80. Paysign, Inc. has a 12 month low of $3.08 and a 12 month high of $14.43.

Paysign (NASDAQ:PAYS) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.05. Paysign had a return on equity of 30.13% and a net margin of 15.67%.The business had revenue of $28.25 million for the quarter, compared to analysts’ expectations of $26.36 million. Paysign has set its FY 2026 guidance at 0.350-0.370 EPS and its Q3 2026 guidance at 0.090-0.100 EPS. As a group, equities research analysts predict that Paysign, Inc. will post 0.58 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on PAYS shares. Weiss Ratings upgraded shares of Paysign from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, July 29th. Lake Street Capital boosted their target price on shares of Paysign from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday. Wall Street Zen lowered shares of Paysign from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 16th. Barrington Research set a $15.00 price objective on Paysign in a report on Tuesday, August 11th. Finally, DA Davidson raised their target price on Paysign from $9.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Paysign presently has a consensus rating of “Buy” and an average target price of $14.00.

Hedge Funds Weigh In On Paysign

A number of large investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in Paysign during the 2nd quarter worth approximately $25,219,000. Punch & Associates Investment Management Inc. bought a new position in Paysign in the 2nd quarter valued at $16,983,000. Renaissance Technologies LLC grew its position in shares of Paysign by 17.4% during the 1st quarter. Renaissance Technologies LLC now owns 1,531,072 shares of the company’s stock valued at $9,033,000 after purchasing an additional 227,300 shares in the last quarter. Thompson Siegel & Walmsley LLC grew its position in shares of Paysign by 14.8% during the 4th quarter. Thompson Siegel & Walmsley LLC now owns 1,457,941 shares of the company’s stock valued at $7,508,000 after purchasing an additional 187,767 shares in the last quarter. Finally, AWM Investment Company Inc. bought a new position in shares of Paysign in the second quarter worth $6,560,000. 25.89% of the stock is currently owned by institutional investors.

Paysign Company Profile

Paysign, Inc is a financial technology company that provides payment and financial services primarily to the healthcare and pharmaceutical industries. Its platform supports prepaid card programs, digital payments and other disbursement solutions designed to help organizations distribute funds to individuals efficiently and securely.

The company’s services include patient assistance programs that help eligible patients receive financial support for prescription medications and other healthcare costs.